European principles of inhibitor management in patients with haemophilia: implications of new treatment options

Orphanet J Rare Dis. 2020 Aug 24;15(1):219. doi: 10.1186/s13023-020-01511-8.

European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD):
J Astermark, M Crato, R d'Oiron, A Dougall, K Fijnvandraat, S Grønhaug, V Jiménez-Yuste, M Jokić, S Lobet, B Nolan, F Peyvandi, A Ryan

¹ Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium. cedric.hermans@uclouvain.be.
² European Haemophilia Consortium, Brussels, Belgium.
³ University of Oxford, Oxford, UK.
⁴ Trinity College, Dublin, Ireland.
⁵ Department of Rehabilitation, Nursing Science and Sports, University Medical Center Utrecht, Utrecht, the Netherlands.
⁶ Canterbury Christ Church University, Kent, UK.
⁷ National Hemophilia Center, Dept. of Hematology and Transfusion Medicine, School of Medicine of Comenius University and University Hospital, Bratislava, Slovakia.
⁸ Children's University Hospital and Masaryk University, Brno, Czech Republic.

No abstract available

Keywords: Bypassing agents; Emicizumab; Factor IX; Factor VIII; Guidelines; Haemophilia; Immune tolerance; Inhibitors.

Publication types